Navigation Links
Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
Date:12/10/2012

SEATTLE Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy, or FSHD, by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease. The protein activity is what damages muscle cells and leads to progressive muscle weakness and atrophy in FSHD patients.

The genetic and disease mechanisms of FSHD were discovered by an international team of scientists led by Stephen Tapscott, M.D., Ph.D., a member of the Fred Hutch Human Biology Division, in a series of studies published between 2010 and early 2012. Tapscott will lead the Fred Hutch work in the GSK collaboration.

The team's discoveries also have implications for developing cancer immunotherapies because researchers also discovered that DUX4 regulates cancer/testis antigens. Cancer/testis antigens are encoded by genes that are normally expressed only in the human germ line but are also abnormally expressed in various tumor types, including melanoma and carcinomas of the bladder, lung and liver. This knowledge will give researchers a way to manipulate the expression of cancer/testis antigens, potentially opening the opportunity to use these antigens in a cancer vaccine.

The partnership with GSK is a first of its kind for Fred Hutch, which is also the first U.S.-based institution to sign on with GSK's "Discovery Partnership with Academia" (DPAc) program. GSK launched the program last year to combine the insight and creativity of the academic world with GSK's drug-discovery expertise to turn innovative research into medicines that benefit patients.

GSK currently has DPAc collaborations in place with Cambridge University and the University of Dundee in the U.K.

U
'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Stem cell research provides hope for infertile cancer survivors
2. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
3. Clinical trial tests rice bran to prevent cancer
4. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
5. Predicting the age at menopause of women having suffered from childhood cancers
6. Research shows immune system response is detrimental to novel brain cancer therapy
7. University of Tennessee researchers find fungus has cancer-fighting power
8. Newly discovered effects of vitamin D on cancer
9. Fruit fly studies guide investigators to misregulated mechanism in human cancers
10. Does your job increase your breast cancer risk?
11. Reconsidering cancers bad guy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/10/2015)... YORK , March 10, 2015  Continuing its ... the Unexpected, Hammacher Schlemmer introduces The Eye Scanning ... identity before granting access to secure websites or sensitive ... to verify travelers at international borders, the device has ... distinctive pattern points of the iris, converting them into ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... deploy a deflector shield to evade enemy attack, tumor cells ... their own to fend off treatments aimed at killing them. ... their armor. , The cells churn out an enzyme that ... damage from radiation or chemotherapy and promotes tumor cell survival. ...
... of antibodies against the Epstein-Barr virus, the virus that ... develop multiple sclerosis 15 to 20 years later, according ... in the June 2006 print issue of Archives of ... long suspected that external factors may influence the risk ...
... new way of looking beneath the ocean surface that ... , A remote sensor system developed by Associate Professor ... MIT, Northeastern University and the Naval Research Laboratory, allows ... well as small schools, over a 10,000-square-kilometer area - ...
Cached Biology News:Molecular force field helps cancer cells defend against attack 2Molecular force field helps cancer cells defend against attack 3Big hips, big belly? It's in your genes, Joslin-led study shows 2One fish, two fish: New MIT sensor improves fish counts 2
(Date:3/30/2015)... NEW BRUNSWICK, N.J. , March 30, 2015 /PRNewswire-USNewswire/ ... research and innovation projects in the state of ... to its next round of grant funding, announced ... existing New Jersey Health Foundation Research Grants program, an ... to $35,000 each to fund early stage research projects ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
... Conn. Two major steps toward putting quantum computers into ... a qubit onto wires and transmitting the signal to a ... team of scientists at Yale. The accomplishments are reported in ... on which it is highlighted as the cover along with ...
... (Nasdaq: PRXL ), a leading global ... of the acquisition,of Taiwan-based APEX International Clinical ... release. In conjunction with the acquisition and ... its forward-looking,financial guidance for the first quarter ...
... 26 Today at the Clinton Global,Initiative ... a,ground-breaking vaccine to eliminate epidemic meningitis in ... developed by the Meningitis,Vaccine Project, a partnership ... produced by Serum Institute of India Limited ...
Cached Biology Technology:Yale scientists make 2 giant steps in advancement of quantum computing 2Yale scientists make 2 giant steps in advancement of quantum computing 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 4PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Corticoliberin...
...
Biology Products: